Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 May;39(5):511–518. doi: 10.1111/j.1365-2125.1995.tb04488.x

Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19.

M Chang 1, G Tybring 1, M L Dahl 1, E Götharson 1, M Sagar 1, R Seensalu 1, L Bertilsson 1
PMCID: PMC1365058  PMID: 7669487

Abstract

1. Fourteen healthy Swedish Caucasian subjects were given 20 mg of omeprazole orally each morning for 8 days. The subjects included five poor metabolisers (PM) of S-mephenytoin, four heterozygous extensive metabolisers (hetEM) and five subjects with a very rapid metabolism (rapidEM). 2. After the first dose, the relative mean areas under the plasma concentration vs time curve (AUC) of omeprazole in rapidEM, hetEM and PM were 1:3.7:20 (all different, P < 0.001). A similar relation was seen in the AUC(0,10 h) of the sulphone metabolite (1:3:12). Concentrations of hydroxyomeprazole were higher in EM than in PM confirming that the hydroxy, but not the sulphone metabolite, is formed by the S-mephenytoin hydroxylase (CYP2C19). After 8 days of treatment, the differences between groups were similar. 3. After both the first and the eighth doses, the omeprazole/hydroxyomeprazole plasma concentration ratio, determined 3 h after drug intake, correlated with the mephenytoin S/R ratio (rs = 0.94; P < 0.001; n = 14) suggesting that omeprazole might be used to phenotype for CYP2C19. 4. After the first dose of omeprazole, there was no difference in the AUC(0,10 h) of plasma gastrin between the three groups. From the first to the eighth dose, the AUC(0,10) of gastrin increased significantly in both hetEM and PM, while there was no change in the rapidEM. After the eighth dose, the AUC(0,10) of gastrin correlated significantly with the AUC of omeprazole in plasma (rs = 0.79; P < 0.01; n = 13).

Full text

PDF
511

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson T., Andrén K., Cederberg C., Lagerström P. O., Lundborg P., Skånberg I. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol. 1990 May;29(5):557–563. doi: 10.1111/j.1365-2125.1990.tb03679.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Andersson T., Miners J. O., Veronese M. E., Tassaneeyakul W., Tassaneeyakul W., Meyer U. A., Birkett D. J. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol. 1993 Dec;36(6):521–530. doi: 10.1111/j.1365-2125.1993.tb00410.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Andersson T., Regårdh C. G., Dahl-Puustinen M. L., Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit. 1990 Jul;12(4):415–416. doi: 10.1097/00007691-199007000-00020. [DOI] [PubMed] [Google Scholar]
  4. Bertilsson L., Dahl M. L., Sjöqvist F., Aberg-Wistedt A., Humble M., Johansson I., Lundqvist E., Ingelman-Sundberg M. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet. 1993 Jan 2;341(8836):63–63. doi: 10.1016/0140-6736(93)92546-6. [DOI] [PubMed] [Google Scholar]
  5. Bertilsson L., Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? Clin Pharmacol Ther. 1993 May;53(5):608–610. doi: 10.1038/clpt.1993.77. [DOI] [PubMed] [Google Scholar]
  6. Bertilsson L., Lou Y. Q., Du Y. L., Liu Y., Kuang T. Y., Liao X. M., Wang K. Y., Reviriego J., Iselius L., Sjöqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther. 1992 Apr;51(4):388–397. doi: 10.1038/clpt.1992.38. [DOI] [PubMed] [Google Scholar]
  7. Broly F., Gaedigk A., Heim M., Eichelbaum M., Morike K., Meyer U. A. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 1991 Oct;10(8):545–558. doi: 10.1089/dna.1991.10.545. [DOI] [PubMed] [Google Scholar]
  8. Cederberg C., Thomson A. B., Mahachai V., Westin J. A., Kirdeikis P., Fisher D., Zuk L., Marriage B. Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology. 1992 Sep;103(3):913–918. doi: 10.1016/0016-5085(92)90025-t. [DOI] [PubMed] [Google Scholar]
  9. Chiba K., Kobayashi K., Manabe K., Tani M., Kamataki T., Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. J Pharmacol Exp Ther. 1993 Jul;266(1):52–59. [PubMed] [Google Scholar]
  10. Dahl M. L., Johansson I., Palmertz M. P., Ingelman-Sundberg M., Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther. 1992 Jan;51(1):12–17. doi: 10.1038/clpt.1992.2. [DOI] [PubMed] [Google Scholar]
  11. Fellenius E., Berglindh T., Sachs G., Olbe L., Elander B., Sjöstrand S. E., Wallmark B. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase. Nature. 1981 Mar 12;290(5802):159–161. doi: 10.1038/290159a0. [DOI] [PubMed] [Google Scholar]
  12. Festen H. P., Thijs J. C., Lamers C. B., Jansen J. M., Pals G., Frants R. R., Défize J., Meuwissen S. G. Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels. Gastroenterology. 1984 Nov;87(5):1030–1034. [PubMed] [Google Scholar]
  13. Goldstein J. A., Faletto M. B., Romkes-Sparks M., Sullivan T., Kitareewan S., Raucy J. L., Lasker J. M., Ghanayem B. I. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry. 1994 Feb 22;33(7):1743–1752. doi: 10.1021/bi00173a017. [DOI] [PubMed] [Google Scholar]
  14. Heim M., Meyer U. A. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet. 1990 Sep 1;336(8714):529–532. doi: 10.1016/0140-6736(90)92086-w. [DOI] [PubMed] [Google Scholar]
  15. Ishizaki T., Sohn D. R., Kobayashi K., Chiba K., Lee K. H., Shin S. G., Andersson T., Regårdh C. G., Lou Y. C., Zhang Y. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit. 1994 Apr;16(2):214–215. doi: 10.1097/00007691-199404000-00018. [DOI] [PubMed] [Google Scholar]
  16. Johansson I., Lundqvist E., Bertilsson L., Dahl M. L., Sjöqvist F., Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11825–11829. doi: 10.1073/pnas.90.24.11825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Küpfer A., Roberts R. K., Schenker S., Branch R. A. Stereoselective metabolism of mephenytoin in man. J Pharmacol Exp Ther. 1981 Jul;218(1):193–199. [PubMed] [Google Scholar]
  18. Lagerström P. O., Persson B. A. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr. 1984 Aug 10;309(2):347–356. doi: 10.1016/0378-4347(84)80042-0. [DOI] [PubMed] [Google Scholar]
  19. Lind T., Cederberg C., Ekenved G., Haglund U., Olbe L. Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man. Gut. 1983 Apr;24(4):270–276. doi: 10.1136/gut.24.4.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lindberg R. L., Juvonen R., Negishi M. Molecular characterization of the murine Coh locus: an amino acid difference at position 117 confers high and low coumarin 7-hydroxylase activity in P450coh. Pharmacogenetics. 1992 Feb;2(1):32–37. doi: 10.1097/00008571-199202000-00006. [DOI] [PubMed] [Google Scholar]
  21. Nilsson G. Increased plasma gastrin levels in connection with inhibition of gastric acid responses to sham feeding following bulbar perfusion with acid in dogs. Scand J Gastroenterol. 1975;10(3):273–277. [PubMed] [Google Scholar]
  22. Relling M. V., Ayers D., Heideman R. L. Mephenytoin phenotyping: lack of haematologic effect and timing of urine collections. Pharmacogenetics. 1991 Oct;1(1):42–49. doi: 10.1097/00008571-199110000-00007. [DOI] [PubMed] [Google Scholar]
  23. Sohn D. R., Kobayashi K., Chiba K., Lee K. H., Shin S. G., Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther. 1992 Sep;262(3):1195–1202. [PubMed] [Google Scholar]
  24. Tybring G., Bertilsson L. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics. 1992 Oct;2(5):241–243. doi: 10.1097/00008571-199210000-00007. [DOI] [PubMed] [Google Scholar]
  25. Ward S. A., Helsby N. A., Skjelbo E., Brøsen K., Gram L. F., Breckenridge A. M. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. Br J Clin Pharmacol. 1991 Jun;31(6):689–692. doi: 10.1111/j.1365-2125.1991.tb05594.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wedlund P. J., Aslanian W. S., McAllister C. B., Wilkinson G. R., Branch R. A. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther. 1984 Dec;36(6):773–780. doi: 10.1038/clpt.1984.256. [DOI] [PubMed] [Google Scholar]
  27. Wrighton S. A., Stevens J. C., Becker G. W., VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch Biochem Biophys. 1993 Oct;306(1):240–245. doi: 10.1006/abbi.1993.1506. [DOI] [PubMed] [Google Scholar]
  28. Zhang Y., Blouin R. A., McNamara P. J., Steinmetz J., Wedlund P. J. Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol. 1991 Mar;31(3):350–352. doi: 10.1111/j.1365-2125.1991.tb05542.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. de Morais S. M., Wilkinson G. R., Blaisdell J., Nakamura K., Meyer U. A., Goldstein J. A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994 Jun 3;269(22):15419–15422. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES